BioWave

Brad Smith launched BioWave in 2007, terrible timing for a capital-intensive medical device startup given the financial crisis. But he had something crucial: a working prototype of electrical stimulation technology that actually relieved pain, developed over several years of R&D and clinical studies. More importantly, he had conviction. He would demonstrate the device to potential investors and their families, letting them experience the results firsthand. That hands-on proof converted skeptics into believers—he raised $6 million from angel investors and venture capitalists, many of whom had personal experience with pain or knew family members who did.

The path to commercialization was rigorous. Brad spent years developing the technology, running clinical studies, obtaining FDA marketing clearance, and perfecting production units before any revenue came in. The device itself is deceptively simple: a handheld unit the size of a hardcover book that delivers therapeutic electrical signals through electrodes placed on the skin, blocking pain signals to the brain—like novocaine but electrical instead of chemical. A 30-minute treatment can provide up to 24 hours of pain relief.

Brad's first customer was the New York Giants in 2007. From there, he personally ran all sales, demonstrating the devices to sports teams and hospitals. The value proposition was immediate: athletes could accelerate rehabilitation, move with less pain through greater ranges of motion, and return to competition faster. By the time of this interview, BioWave had penetrated 30-32 NFL teams, 24 NBA teams, 24 Major League Baseball teams, and 34 VA hospitals.

The breakthrough came when Brad raised an additional $1.6 million two years prior (approximately 2015-2016) to build a professional sales team. Early on, Brad had been the sole salesman, which limited growth. The new capital funded experienced sales leadership, proper marketing, and a network of over 70 distributors selling to pain clinics, spine centers, and VA hospitals. The business model proved highly profitable through recurring revenue: gel pads at $15 per pair (consumed frequently across teams), and the premium percutaneous needle electrodes at $150 per pair (95% of hospital market revenue, reimbursable by insurance at ~$450 per treatment). An NFL team might spend $18,000+ annually on devices (half a dozen pro units at $3,500 each) plus $7,500+ per season on electrode packs. The VA market became particularly valuable—veterans try the device in clinic, and if effective, the hospital purchases $895 home units for ongoing opioid-free pain management.

With 16 full-time employees and $7.6 million raised total, BioWave was projected to exceed $5 million in annual revenue in the year of this interview, representing 2.5x growth year-over-year following the sales team build-out. The company had established itself as the credible choice in pain management—when a hospital in Florida wants to convince a patient that electrical stimulation works, they point to the Miami Dolphins using BioWave. Brad's next step was positioning for a liquidity event: either going public or selling to a strategic acquirer already in the pain management space who could leverage BioWave's distribution channels and product portfolio for exponential growth.